Cargando…

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice

BACKGROUND: We have shown that insertion of the three vaccinia virus (VACV) promoter-driven foreign gene expression cassettes encoding Renilla luciferase-Aequorea GFP fusion protein, β-galactosidase, and β-glucuronidase into the F14.5L, J2R, and A56R loci of the VACV LIVP genome, respectively, resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Nanhai G, Yu, Yong A, Zhang, Qian, Szalay, Aladar A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192684/ https://www.ncbi.nlm.nih.gov/pubmed/21951588 http://dx.doi.org/10.1186/1479-5876-9-164

Ejemplares similares

Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps
por: Kober, Christina, et al.
Publicado: (2015)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice
por: Hofmann, Elisabeth, et al.
Publicado: (2014)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
por: Wang, Huiqiang, et al.
Publicado: (2012)

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
por: Zhang, Qian, et al.
Publicado: (2009)

Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
por: Ehrig, Klaas, et al.
Publicado: (2013)

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Oncolytic Viruses
por: Chen, Nanhai G., et al.
Publicado: (2012)

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2011)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
por: Gentschev, Ivaylo, et al.
Publicado: (2012)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
por: Haddad, Dana, et al.
Publicado: (2016)

Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models
por: Cecil, Alexander, et al.
Publicado: (2019)

Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
por: Haddad, Dana, et al.
Publicado: (2011)

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
por: Donat, Ulrike, et al.
Publicado: (2012)

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
por: Worschech, Andrea, et al.
Publicado: (2009)

Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter
por: Haddad, Dana, et al.
Publicado: (2012)

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
por: Adelfinger, Marion, et al.
Publicado: (2014)

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2016)

Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
por: Schäfer, Simon, et al.
Publicado: (2012)

A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter
por: Jun, Kyong-Hwa, et al.
Publicado: (2014)

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
por: Ascierto, Maria Libera, et al.
Publicado: (2011)

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
por: Huang, Ting, et al.
Publicado: (2015)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
por: Kober, Christina, et al.
Publicado: (2015)

Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival
por: Duggal, Rohit, et al.
Publicado: (2013)

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
por: Patil, Sandeep S., et al.
Publicado: (2012)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
por: Adelfinger, Marion, et al.
Publicado: (2015)

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2019)

Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
por: Tsoneva, Desislava, et al.
Publicado: (2017)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
por: Liu, Liqiong, et al.
Publicado: (2022)

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2021)

Efficient Selection of Recombinant Fluorescent Vaccinia Virus Strains and Rapid Virus Titer Determination by Using a Multi-Well Plate Imaging System
por: Ye, Mingyu, et al.
Publicado: (2021)

Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus
por: Ma, Jing, et al.
Publicado: (2021)

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas
por: Petrov, Ivan, et al.
Publicado: (2020)

Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains
por: Wang, Huiqiang, et al.
Publicado: (2013)

Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL‐24 gene in liver cancer cells
por: Wang, Chunming, et al.
Publicado: (2020)

Oncolytic Virotherapy of Canine and Feline Cancer
por: Gentschev, Ivaylo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vsvfqb2ntvja2asoscvfit1m1o